| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4da492073da12347757cdf821512a01a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97bd68cb0a98913a5940c708e7ce1679
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c87b1f7158bec499783fa1b27aad08c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 |
| filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d3588c4709948d85bd66bd711aef881
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3c4035f3e5f9b25dd842f4145ecbcc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_377c1230cc5b9d21d30ae235fd59dcdd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09a64454104b03f720127a6c0129b190
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_830b7b8ce8a072f2dc875d8b756752bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be74a2969cb379d9870d959cae283331
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7694549c4e07cca8ffc825e8111e14ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2901aa9e32ce80240b6c22f4509786a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3556366a24e2063c1ec96cb69a695d8a |
| publicationDate |
2017-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9763921-B2 |
| titleOfInvention |
Dosing regimens of celgosivir for the treatment of dengue |
| abstract |
Methods of treating a dengue virus (DENV) infection in a human subject, comprising administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound of Formula (I) can be administered within onset of fever to 72 hours of fever onset due to dengue infection and then every 6 to 12 hours until there is an improvement in the infection or between from about 1 day to about 10 days. The methods of the invention can be used to treat primary and secondary DENV1-4 viral infections. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018064693-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11219616-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10517854-B2 |
| priorityDate |
2013-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |